TD:
Sorry, didn't show sufficient respect for your post with my last answer. I was in still in shock from Lilly to Merck whiplash, sorry.
- g -
>> What's intriguing to me is: Why SIBI? Why MRK? <<
Yeah. Lilly deal, licenses for Txn up their wazoo, Pfizer lawsuit, OSIP PNU license, and now a sales price that would seem to cover only the patent, if the patent is "sound". I feel like I've been riding a bumper car with the brakes and steering wheel removed. When this story gets sorted out, we'll be revisiting the thread with an "I get it now!" or two.
>> MRK is looking to open a facility in San Diego (Novartis, JNJ, and WLA all have
one at this point) and this is a cheap way to do it. <<
Sounds good. But, I do have a bias that it was SIBI's science that was attractive, not their location.
>> Who's next, and who would they
buy? <<
Norartis will buy EPIcyte for $24.1 billion.
>> MRK was "infringing" the SIBI patent and found one or more blockbuster drugs
doing so. Buying the company outright was judged to be cheaper than paying
royalties down the line. <<
Nah, doesn't feel right. If that's correct, tar and feather will be too good for Comer.
>> What other potential sleeper patents are out there? <<
OSIP?
>> SIBI pitched one of their programs/advanced compounds that impressed MRK so
much they bought the company outright. But those are usually pretty public (see:
SUGN & AGPH). <<
Well, SIBI is such a secretive company...... "pretty public" for them was glancing right and left as they left a conference room (one exception was a presentation at the '98 annual meeting where forward-looking statements were just a tad optimistic for Novartis and BMY).
>> Maybe this belongs on the Munch thread, but this thread will be history soon anyway. <<
Life without AGPH *and* SIBI? Sigh.
>> Kind of OT: Any guesses how many Merck/Rahway employees are going to be interested in becoming Merck/La Jolla employees? <<
70%
Rick |
